A basic principle of neuroscience is that information is stored and encoded by the properties of neurons and the connections they make with one another. Thus, identifying patterns of neuronal connectivity is requisite for understanding brain function. In order to piece together these patterns, information describing both circuit anatomy and the flow of neuronal activity are essential. Several elegant technologies have recently emerged that allow for both trans-synaptic circuit analysis and precise control of neuronal firing
12, including the use of retrogradely transported viral vectors
25,26,27, optogenetic tools such as light-activated ion channels
28,29,30, and heterologous receptor activation
28,31,32.
Advances in viral vector engineering have exploited neurotropic viral particles as tools to study synaptic connectivity
33 (). For example, engineered pseudorabies vectors can be modified to express FPs and thus label interconnected neurons by retrograde trans-synaptic transfer of viral particles to presynaptic cells
25. One limitation to using pseudorabies virus is its polysynaptic spread. Due to the high degree of neuronal interconnectivity in intact circuits, polysynaptic spread makes it difficult to unambiguously assign synaptically coupled partners. Circumventing this problem, Wickersham et al. devised a novel coat protein complementation strategy that allows monosynaptic tracing of neural connections by using rabies virus particles engineered to express GFP
27 ().
Beyond enabling more detailed analysis of anatomy and synaptic connectivity, genetic methods are now being harnessed to facilitate selective control of activity among populations of interconnected neurons in the mammalian brain. Alongside the new subdiscipline in neuroscience aptly coined optogenetics (see accompanying review by K. Deisseroth), efforts to develop novel heterologous receptor expression systems now provide alternative and potentially non-invasive means to modulate neuronal activity using chemical-genetic approaches. Heterologous expression of modified opiate receptors provided an initial demonstration that neuronal subsets in the brains of mice could be genetically targeted for activation by synthetic, exogenous ligands
34. Other studies have used overexpression of endogenous receptors to amplify neuronal subtype-specific neurotransmission. For example, mice engineered to harbor high affinity acetylcholine receptors (nAChRs) in dopaminergic neurons show hyperdopaminergic behavior upon low-dose administration of nicotine
35. Further, conditional expression and activation of the rat capsaicin receptor TRPV1 in genetically targeted subsets of neurons in the mouse brain has provided the ability to stimulate desired neuronal populations in a conditional Cre-dependent manner
28. Complementing these strategies has been the engineering of different G-protein coupled receptor (GPCR) families to respond to synthetic drug-like compounds
36.
For many applications, inhibition rather than excitation of genetically defined neuronal populations is desired. To this end, a number of methods have been developed for
in vivo experimentation. One such model takes advantage of wildtype GABA
A receptor sensitivity to the allosteric modulator zolpidem, which normally enhances receptor function. In this design a conditional mouse model was generated that harbors a point mutation in the GABA
A receptor γ2 subunit making it insensitive to zolpidem. Upon Cre-mediated recombination, wildtype receptor activity is reinstated to genetically targeted neuronal subsets, rendering those cells sensitive to pharmacological inhibition by zolpidem
37. Orthogonal models have been used to drive neuronal hyperpolarization and inhibit action potential generation by heterologous expression of the
C. elegans ivermectin-gated chloride channel
31, or the
Drosophila allostatin receptor, which inactivates neurons by opening G protein-coupled inward-rectifying K
+ channels
32. An alternate strategy has been to block synaptic transmission rather than induce hyperpolarization. Genetic expression of small-molecules for inactivation of synaptic transmission, or expression of
Clostridium toxin fragments, has allowed selective inactivation of targeted synapses
38,39,40.
Each of these approaches has unique limitations. For example, controlled inhibition by ivermectin-gated chloride channels relies on the availability of multiple subunits whose functionality requires the appropriate stoichiometry. On the other hand, small molecule-mediated inhibition of synapses
39, which induces dimerization of genetically modified forms of presynaptic proteins, shows toxicity with prolonged exposure of dimerizer at high concentrations. Further, ligand application for neuronal activation requires transport across the blood brain barrier (BBB) and is concentration-dependent. Interestingly, the mouse model system for genetic control of neuronal activity by conditional TRPV1 expression may obviate some of these limitations. Multiple TRPV1 agonists and antagonists with an array of different binding affinities, solubilities, and BBB permeabilities offer the potential for pharmacogenetic manipulations of deep and disperse neuronal populations in a potentially noninvasive manner. A similar advantage in BBB permeability exists for compounds that activate engineered GPCRs
36.